Literature DB >> 30092854

Development and Characterization of a Model for Inducing Fetal Hemoglobin Production in Cynomolgus Macaques (Macaca fasicularis).

Mila C Kundu1, Liz R Gore2, Sean Maguire3, Aidan G Gilmartin2.   

Abstract

Hydroxyurea induces production of fetal hemoglobin (HbF), a tetramer of α and γ globin proteins and corresponding heme molecules, normally found in less than 1% of adult RBC. Increases in circulating HbF are correlated with clinical improvement of patients with hemoglobinopathies, and hydroxyurea, as a daily medication, is the standard treatment for sickle cell anemia. Although olive baboons (Papio anubis) are considered a key model species for HbF induction, cynomolgus macaques (Macaca fasicularis) are another species that conserves the ability to produce HbF into maturity. In this study, moderate anemia was experimentally induced in cynomolgus macaques by phlebotomy, to stimulate accelerated erythropoiesis and HbF production. In contrast to previous studies, vascular access ports were implanted for phlebotomy of conscious monkeys, followed by fluid replacement. As total Hgb levels dropped, reticulocyte counts and the percentage of HbF-expressing cells increased. Once total Hgb levels declined to less than 8 g/dL, 2 courses of oral hydroxyurea (once daily for 5 d) were completed, with a 9-d interval between courses. After hydroxyurea dosing, the percentage of HbF-expressing cells and total HbF were increased significantly. In addition, a significant but transient decrease in reticulocyte count and a transient increase in MCV occurred, replicating the characteristic response of patients receiving hydroxyurea. Daily clinical observations revealed no serious health issues or decreases in food consumption or activity levels. Methods were established for assessing the patency of vascular access ports. This study details a new protocol for the safe and routine induction of moderate anemia in cynomolgus macaques and validates its use in the investigation of novel pharmacologic entities to induce the production of HbF.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30092854      PMCID: PMC6200035          DOI: 10.30802/AALAS-CM-17-000124

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  22 in total

1.  Knockout-transgenic mouse model of sickle cell disease.

Authors:  T M Ryan; D J Ciavatta; T M Townes
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

2.  Effects of weekly blood collection in male and female cynomolgus macaques (Macaca fascicularis).

Authors:  Cynthia R Adams; Lisa C Halliday; Elizabeth A Nunamaker; Jeffrey D Fortman
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-01       Impact factor: 1.232

3.  Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model.

Authors:  Jeffrey D Lebensburger; Tamara I Pestina; Russell E Ware; Kelli L Boyd; Derek A Persons
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

4.  Chronic anemia and effects of iron supplementation in a research colony of adult Rhesus macaques (Macaca mulatta).

Authors:  Michelle L Turk; Robert Simoni; Laura Cacioppo; Robert P Marini; Mary M Patterson
Journal:  Comp Med       Date:  2012-04       Impact factor: 0.982

5.  Development of primitive and definitive hematopoiesis from nonhuman primate embryonic stem cells in vitro.

Authors:  Katsutsugu Umeda; Toshio Heike; Momoko Yoshimoto; Mitsutaka Shiota; Hirofumi Suemori; Hong Yuan Luo; David H K Chui; Ryuzo Torii; Masabumi Shibuya; Norio Nakatsuji; Tatsutoshi Nakahata
Journal:  Development       Date:  2004-04       Impact factor: 6.868

6.  Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea.

Authors:  N L Letvin; D C Linch; G P Beardsley; K W McIntyre; D G Nathan
Journal:  N Engl J Med       Date:  1984-04-05       Impact factor: 91.245

Review 7.  Pharmacotherapy in sickle cell disease--state of the art and future prospects.

Authors:  Jane Hankins; Banu Aygun
Journal:  Br J Haematol       Date:  2009-02-17       Impact factor: 6.998

Review 8.  Hydroxyurea therapy for sickle cell anemia.

Authors:  Patrick T McGann; Russell E Ware
Journal:  Expert Opin Drug Saf       Date:  2015-09-14       Impact factor: 4.250

9.  Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo.

Authors:  Betty S Pace; Gary L White; George J Dover; Michael S Boosalis; Douglas V Faller; Susan P Perrine
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

Review 10.  Primitive and definitive erythropoiesis in mammals.

Authors:  James Palis
Journal:  Front Physiol       Date:  2014-01-28       Impact factor: 4.566

View more
  1 in total

1.  Discovery of DS79932728: A Potent, Orally Available G9a/GLP Inhibitor for Treating β-Thalassemia and Sickle Cell Disease.

Authors:  Katsushi Katayama; Ken Ishii; Hideki Terashima; Eisuke Tsuda; Makoto Suzuki; Keiichi Yotsumoto; Kumiko Hiramoto; Isao Yasumatsu; Munefumi Torihata; Takashi Ishiyama; Tsuyoshi Muto; Takahiro Katagiri
Journal:  ACS Med Chem Lett       Date:  2020-12-28       Impact factor: 4.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.